Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Procalcitonin, mid-regional proadrenomedullin and C-reactive protein in predicting treatment outcome in community-acquired febrile urinary tract infection.

Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, van der Reijden TJK, Delfos NM, Leyten EMS, Koster T, Ablij HC, van 't Wout JJW, van Dissel JT.

BMC Infect Dis. 2019 Feb 14;19(1):161. doi: 10.1186/s12879-019-3789-6.

2.

Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial.

Boerekamps A, De Weggheleire A, van den Berk GE, Lauw FN, Claassen MAA, Posthouwer D, Bierman WF, Hullegie SJ, Popping S, van de Vijver DACM, Dofferhoff ASM, Kootstra GJ, Leyten EM, den Hollander J, van Kasteren ME, Soetekouw R, Ammerlaan HSM, Schinkel J, Florence E, Arends JE, Rijnders BJA.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):269-277. doi: 10.1016/S2468-1253(18)30414-X. Epub 2019 Jan 17.

PMID:
30660617
3.

Borderline QuantiFERON results and the distinction between specific responses and test variability.

Uzorka JW, Bossink AWJ, Franken WPJ, Thijsen SFT, Leyten EMS, van Haeften AC, Doornenbal G, Boonstra P, Ottenhoff THM, Arend SM.

Tuberculosis (Edinb). 2018 Jul;111:102-108. doi: 10.1016/j.tube.2018.06.002. Epub 2018 Jun 7.

4.

Biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection.

Stalenhoef JE, van Nieuwkoop C, Wilson DC, van der Starre WE, Delfos NM, Leyten EMS, Koster T, Ablij HC, Van't Wout JJW, van Dissel JT.

J Infect. 2018 Jul;77(1):18-24. doi: 10.1016/j.jinf.2018.05.007. Epub 2018 May 26.

5.

Dynamics of colistin and tobramycin resistance among Enterobacter cloacae during prolonged use of selective decontamination of the digestive tract.

Dautzenberg MJD, Bayjanov JR, Leverstein-van Hall MA, Muller AE, Gelinck LBS, Jansen CL, Leyten EMS, Ruys T, Scharringa J, van der Starre RE, Fluit AC, Bonten MJM.

Antimicrob Resist Infect Control. 2018 May 22;7:67. doi: 10.1186/s13756-018-0356-7. eCollection 2018.

6.

Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy.

Boerekamps A, van den Berk GE, Lauw FN, Leyten EM, van Kasteren ME, van Eeden A, Posthouwer D, Claassen MA, Dofferhoff AS, Verhagen DWM, Bierman WF, Lettinga KD, Kroon FP, Delsing CE, Groeneveld PH, Soetekouw R, Peters EJ, Hullegie SJ, Popping S, van de Vijver DAMC, Boucher CA, Arends JE, Rijnders BJ.

Clin Infect Dis. 2018 Apr 17;66(9):1360-1365. doi: 10.1093/cid/cix1007.

PMID:
29186320
7.

Hospitalization for community-acquired febrile urinary tract infection: validation and impact assessment of a clinical prediction rule.

Stalenhoef JE, van der Starre WE, Vollaard AM, Steyerberg EW, Delfos NM, Leyten EMS, Koster T, Ablij HC, Van't Wout JW, van Dissel JT, van Nieuwkoop C.

BMC Infect Dis. 2017 Jun 6;17(1):400. doi: 10.1186/s12879-017-2509-3.

8.

Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.

van Nieuwkoop C, van der Starre WE, Stalenhoef JE, van Aartrijk AM, van der Reijden TJ, Vollaard AM, Delfos NM, van 't Wout JW, Blom JW, Spelt IC, Leyten EM, Koster T, Ablij HC, van der Beek MT, Knol MJ, van Dissel JT.

BMC Med. 2017 Apr 3;15(1):70. doi: 10.1186/s12916-017-0835-3.

9.

Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients.

Hullegie SJ, Claassen MA, van den Berk GE, van der Meer JT, Posthouwer D, Lauw FN, Leyten EM, Koopmans PP, Richter C, van Eeden A, Bierman WF, Newsum AM, Arends JE, Rijnders BJ.

J Hepatol. 2016 Apr;64(4):807-12. doi: 10.1016/j.jhep.2015.12.004. Epub 2015 Dec 12.

PMID:
26689767
10.

Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014.

Hullegie SJ, van den Berk GEL, Leyten EMS, Arends JE, Lauw FN, van der Meer JTM, Posthouwer D, van Eeden A, Koopmans PP, Richter C, van Kasteren MEE, Kroon FP, Bierman WFW, Groeneveld PHP, Lettinga KD, Soetekouw R, Peters EJG, Verhagen DWM, van Sighem AI, Claassen MAA, Rijnders BJA.

Clin Microbiol Infect. 2016 Feb;22(2):209.e1-209.e3. doi: 10.1016/j.cmi.2015.10.012. Epub 2015 Oct 17.

11.

Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus-Infected Returning Travelers, the Netherlands, 2014.

Mollers M, Jonges M, Pas SD, van der Eijk AA, Dirksen K, Jansen C, Gelinck LB, Leyten EM, Thurkow I, Groeneveld PH, van Gageldonk-Lafeber AB, Koopmans MP, Timen A; MERS-CoV Outbreak Investigation Team of the Netherlands.

Emerg Infect Dis. 2015 Sep;21(9):1667-9. doi: 10.3201/eid2109.150560.

12.

Prognostic value of pro-adrenomedullin, procalcitonin and C-reactive protein in predicting outcome of febrile urinary tract infection.

van der Starre WE, Zunder SM, Vollaard AM, van Nieuwkoop C, Stalenhoef JE, Delfos NM, Van't Wout JW, Spelt IC, Blom JW, Leyten EM, Koster T, Ablij HC, van Dissel JT.

Clin Microbiol Infect. 2014 Oct;20(10):1048-54. doi: 10.1111/1469-0691.12645.

13.

Diabetes and the course of febrile urinary tract infection.

van der Starre WE, Borgdorff H, Vollaard AM, Delfos NM, van 't Wout JW, Spelt IC, Blom JW, Leyten EM, Koster T, Ablij HC, van Dissel JT, van Nieuwkoop C.

Diabetes Care. 2013 Dec;36(12):e193-4. doi: 10.2337/dc13-0903. No abstract available.

14.

A soft-tissue mass on the forehead. Rare presentation of extrapulmonary tuberculosis (EPTB)/Pott's disease.

Nadery S, Leyten EM.

Neth J Med. 2011 Jul-Aug;69(7):345, 348. No abstract available.

15.

A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients.

de Vries-Sluijs TE, Hansen BE, van Doornum GJ, Kauffmann RH, Leyten EM, Mudrikova T, Brinkman K, den Hollander JG, Kroon FP, Janssen HL, van der Ende ME, de Man RA.

J Infect Dis. 2011 Apr 1;203(7):984-91. doi: 10.1093/infdis/jiq137. Epub 2011 Jan 25.

PMID:
21266513
16.

Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.

van der Starre WE, van Nieuwkoop C, Paltansing S, van't Wout JW, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, Blom JW, van Dissel JT.

J Antimicrob Chemother. 2011 Mar;66(3):650-6. doi: 10.1093/jac/dkq465. Epub 2010 Dec 1.

PMID:
21123286
17.

Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study.

van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Leyten EM, van Dissel JT.

Crit Care. 2010;14(6):R206. doi: 10.1186/cc9328. Epub 2010 Nov 17.

18.

An abdominal mass: not a 'clear cut' case! Actinomycosis.

Heidt J, Jansen CL, Leyten EM.

Neth J Med. 2010 Oct;68(10):319-21. No abstract available.

19.

Predicting the need for radiologic imaging in adults with febrile urinary tract infection.

van Nieuwkoop C, Hoppe BP, Bonten TN, Van't Wout JW, Aarts NJ, Mertens BJ, Leyten EM, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Elzevier HW, van Dissel JT.

Clin Infect Dis. 2010 Dec 1;51(11):1266-72. doi: 10.1086/657071. Epub 2010 Oct 29.

PMID:
21034195
20.

Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days).

van Nieuwkoop C, van't Wout JW, Assendelft WJ, Elzevier HW, Leyten EM, Koster T, Wattel-Louis GH, Delfos NM, Ablij HC, Kuijper EJ, Pander J, Blom JW, Spelt IC, van Dissel JT.

BMC Infect Dis. 2009 Aug 19;9:131. doi: 10.1186/1471-2334-9-131.

21.

A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment.

Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT.

Clin Infect Dis. 2007 Dec 1;45(11):1470-5. Epub 2007 Oct 25.

PMID:
17990230
22.

Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation.

Leyten EM, Arend SM, Prins C, Cobelens FG, Ottenhoff TH, van Dissel JT.

Clin Vaccine Immunol. 2007 Jul;14(7):880-5. Epub 2007 May 16.

23.

T-cell recognition of the HspX protein of Mycobacterium tuberculosis correlates with latent M. tuberculosis infection but not with M. bovis BCG vaccination.

Geluk A, Lin MY, van Meijgaarden KE, Leyten EM, Franken KL, Ottenhoff TH, Klein MR.

Infect Immun. 2007 Jun;75(6):2914-21. Epub 2007 Mar 26.

24.

Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay.

Leyten EM, Prins C, Bossink AW, Thijsen S, Ottenhoff TH, van Dissel JT, Arend SM.

Eur Respir J. 2007 Jun;29(6):1212-6. Epub 2007 Jan 10.

25.

Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contacts.

Arend SM, Thijsen SF, Leyten EM, Bouwman JJ, Franken WP, Koster BF, Cobelens FG, van Houte AJ, Bossink AW.

Am J Respir Crit Care Med. 2007 Mar 15;175(6):618-27. Epub 2006 Dec 14.

PMID:
17170386
26.

Human T-cell responses to 25 novel antigens encoded by genes of the dormancy regulon of Mycobacterium tuberculosis.

Leyten EM, Lin MY, Franken KL, Friggen AH, Prins C, van Meijgaarden KE, Voskuil MI, Weldingh K, Andersen P, Schoolnik GK, Arend SM, Ottenhoff TH, Klein MR.

Microbes Infect. 2006 Jul;8(8):2052-60. Epub 2006 Jun 13.

PMID:
16931093
27.

Use of enzyme-linked immunospot assay with Mycobacterium tuberculosis-specific peptides for diagnosis of recent infection with M. tuberculosis after accidental laboratory exposure.

Leyten EM, Mulder B, Prins C, Weldingh K, Andersen P, Ottenhoff TH, van Dissel JT, Arend SM.

J Clin Microbiol. 2006 Mar;44(3):1197-201.

28.

Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis.

Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen P, Doherty TM; VACSEL Study Group.

Clin Vaccine Immunol. 2006 Feb;13(2):179-86.

29.

Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.

Leyten EM, Soonawala D, Schultsz C, Herzog C, Ligthelm RJ, Wijnands S, Visser LG.

Vaccine. 2005 Oct 17;23(43):5120-6.

PMID:
15982790
30.

Specific T-cell epitopes for immunoassay-based diagnosis of Mycobacterium tuberculosis infection.

Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P.

J Clin Microbiol. 2004 Jun;42(6):2379-87.

31.

Reverse smoking as a risk factor for palatal cancer: a cross-sectional study in rural Andhra Pradesh, India.

van der Eb MM, Leyten EM, Gavarasana S, Vandenbroucke JP, Kahn PM, Cleton FJ.

Int J Cancer. 1993 Jul 9;54(5):754-8.

PMID:
8325705

Supplemental Content

Loading ...
Support Center